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Background
Acquired angioedema (AAE) is a rare disorder caused
by acquired deficiency of C1 inhibitor (C1-INH), very
often seen in association with lymphoproliferative dis-
eases. The key elements of AAE are acquired deficiency
of C1 inhibitor, hyperactivation of the classical pathway
of complement, and recurrent angioedema symptoms.
Case presentation
We report a case of Waldenstrom´s macroglobulinemia
causing an acquired deficiency of C1 esterase inhibitor in a
40-year-old woman. She initially presented with an episode
of angioedema followed by many episodes of abdominal
distention associated with pain, vomiting, and diarrhea for
1.5 years. Work-up revealed low C1 esterase inhibitor
levels, normal C3, and nonexistent C4. A diagnosis of
acquired C1 esterase inhibitor deficiency was proposed at
the time. However, it was also noted that her IgM was very
elevated with an IgM monoclonal gammopathy with kappa
light chains, and an enlarged spleen. Bone marrow biopsy
and aspirate revealed clonal B-cells staining positively for
CD20. She was diagnosed with Waldenstrom´s macroglo-
bulinemia in association with C1 esterase inhibitor defi-
ciency. Although the association is recognized, it is rare,
and likely secondary to antibodies against C1 esterase inhi-
bitor. After treatment with rituximab, cyclophosphamide,
and prednisone, her paraprotein levels fell to normal range,
and her autoimmune parameters normalized with signifi-
cant clinical improvement. She has not had any further
episodes of angioedema. She will continue on rituximab as
maintenance therapy for 2 more years.
Conclusion
Acquired deficiency of C1 esterase inhibitor is quite rare
with just over 100 cases in the literature. Given that most
cases are related to antibodies against C1 esterase inhibi-
tor, rituximab may be the treatment of choice. However,
treatment of the underlying lymphoproliferative disorder
may need to be considered as well and could provide a
more definitive treatment.
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